Santé log1h
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
CMND-100, a proprietary MEAI-based oral drug candidate, represents a potential breakthrough in AUD treatment, targeting the reduction of alcohol consumption and cravings through a novel mechanism of ...
Santé log1h
Bright Green Corporation Announces the next steps for the completion of its restructuring plan
Lynn Stockwell, the new Chief Executive Officer and Chairman of the Board of Directors of Bright Green Corporation, is also the CEO, Chair and sponsors and manages other NASDAQ listed corporations ...
Santé log1h
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
Additional approximately $21 million tied to data release for the Company’s BEST1 program. RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. ( ...
Santé log1h
Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX
As previously reported, the LYNX-1 Phase 3 study met its primary endpoint, with a statistically significant greater percentage of Phentolamine Ophthalmic Solution 0.75%-treated participants gaining 15 ...
Santé log1h
Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030
Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030 In 2023, pharmaceutical companies invested more than EUR 460 million in Finland, half of which ...
Santé log1h
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
Dr. Khoja commented, “Fibroblasts are a critical component of the extracellular matrix with regenerative and immunomodulatory properties. Our presentation will detail the progress we’ve made in ...
Santé log1h
PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington
PharmAla is furthermore pleased to announce that Mr. Ali Taghva will take on new responsibilities, acting as Chief Commercial Officer to the Company, as well as Counsel to the Company. For more ...
Santé log1h
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels. SAN FRANCISCO, March 21, 2025 (GLOBE NEW ...
Santé log1h
Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR
Poster underscores Tivoxavir Marboxil’s potential for the treatment of bird flu, supported by 100% survival in a rodent challenge model, potent suppression of resistant viruses and Phase 1 data Full ...
Santé log1h
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category
Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the 'Cell & ...
Santé log1h
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update
Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today ...
Santé log1h
Vireo Growth Inc. Files Definitive Information Circular and Provides Merger Transaction Updates
Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced several updates regarding its previously-announced acquisition transactions (collectively, the “Merger ...